Dapagliflozin does not impair LDL catabolism and induces a shift towards a closer to normal VLDL(1)/VLDL(2) catabolism in individuals with type 2 diabetes: a randomised in vivo kinetic study.
- DOI
- 10.1007/s00125-026-06810-6
- Published
- 2026 Jul 17
- Container
- Diabetologia
- Publisher
- Not recorded
- Open access
- unknown
Credibility signals
limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1007/s00125-026-06810-6,
title = {Dapagliflozin does not impair LDL catabolism and induces a shift towards a closer to normal VLDL(1)/VLDL(2) catabolism in individuals with type 2 diabetes: a randomised in vivo kinetic study.},
author = {Vergès B and Rouland A and Bouillet B and Pais de Barros JP and Fourmont C and Buffier P and Jourdan T and Vergas V and Duvillard L},
year = {2026},
journal = {Diabetologia},
doi = {10.1007/s00125-026-06810-6},
url = {https://doi.org/10.1007/s00125-026-06810-6}
}RIS
TY - JOUR TI - Dapagliflozin does not impair LDL catabolism and induces a shift towards a closer to normal VLDL(1)/VLDL(2) catabolism in individuals with type 2 diabetes: a randomised in vivo kinetic study. AU - Vergès B AU - Rouland A AU - Bouillet B AU - Pais de Barros JP AU - Fourmont C AU - Buffier P AU - Jourdan T AU - Vergas V AU - Duvillard L PY - 2026 JO - Diabetologia DO - 10.1007/s00125-026-06810-6 UR - https://doi.org/10.1007/s00125-026-06810-6 ER -
APA
B, V., A, R., B, B., JP, P. D. B., C, F., P, B., T, J., V, V., & L, D. (2026). Dapagliflozin does not impair LDL catabolism and induces a shift towards a closer to normal VLDL(1)/VLDL(2) catabolism in individuals with type 2 diabetes: a randomised in vivo kinetic study.. Diabetologia. https://doi.org/10.1007/s00125-026-06810-6
Source records
- pubmed · retrieved 2026-09-27T06:44:38.184Z